Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study.

Trial Profile

Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2012

At a glance

  • Drugs Cladribine (Primary) ; Idarubicin (Primary) ; Filgrastim
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 05 Oct 2009 Additional lead trial investigators Harris M and Kamalakar P identified as reported by New Jersey Cancer Trial Connect.
    • 17 Feb 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 17-Feb-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top